EraGen Biosciences signs licensing agreement with Illumina

Posted on: Thu, 19 Nov 2009 13:51:00 EST


Symbols: ILMN
Nov 19, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --
ILMN | Quote | Chart | News | PowerRating -- EraGen Biosciences, Inc., a biotechnology company that develops, manufactures and markets molecular reagent products and software, has signed a licensing agreement with Illumina, Inc., a developer of array-based solutions for DNA, RNA and protein analysis. Both the companies are based in the US.

Under the terms of the agreement, EraGen Biosciences will have access to Illumina's BeadXpress platform. EraGen will use this platform for the continued development and commercialization of molecular-based clinical multiplexed assays with its patented MultiCode(R)-PLx technology.

Deal Type    Partnership
Sub-Category Licensing Agreement
Deal Status Announced: 2009-11-18

Deal Participants

Partner 1 (Company) Illumina, Inc.
Partner 2 (Company) EraGen Biosciences, Inc.

Deal Rationale

This alliance is part of EraGen's strategy to continue to expand its commercial efforts in the molecular diagnostics market.

For full details on Illumina Inc (ILMN) ILMN. Illumina Inc (ILMN) has Short Term PowerRatings at TradingMarkets. Details on Illumina Inc (ILMN) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.